Alzheimer’s

#ABPI #Alzheimer's #Clinical trial #Metabolomics #National Institute for Health and Care Excellence (NICE) #Neurodegenerative disorders #Peptides #UK government #US government

DDW Highlights: 9 December 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a trade agreement between the UK and the US promised to support… Read More

#Podcasts

#ABPI #Alzheimer's #Clinical trial #Metabolomics #National Institute for Health and Care Excellence (NICE) #Neurodegenerative disorders #Peptides #UK government #US government

This week in Drug Discovery (1 – 5 December) 

News round-up for 1 – 5 December by Bruno Quinney, Content Team at DDW.  This week in DDW, a trade agreement between the UK and the US promises to support the life sciences industry and secure access to drugs. Elsewhere, novel therapies could break new ground in treating neurodegenerative diseases.  The… Read More

#News

#AlzeCure Pharma #Alzheimer's #Clinical trial

AlzeCure receives €2.5 million to advance Alzheimer’s drug 

Pharmaceutical company AlzeCure has received a €2.5 million grant from the European Innovation Council (EIC) to advance the Phase II trial of an Alzheimer’s disease treatment.  AlzeCure will advance the candidate NeuroRestore ACD856 to a Phase II trial, developed to improve patients’ learning and memory function and affect the course of disease… Read More

#Business & Investment #News

Peptide
#AltPep Corporation #Alzheimer's #Neurodegenerative disorders #Peptides

Custom-designed peptide could treat Alzheimer’s 

New findings show a custom-designed peptide has promising potential as a treatment for early Alzheimer’s disease (AD).  The candidate SOBIN-AD, developed by biotechnology company AltPep Corporation, demonstrated potential to improve cognition both before and after the onset of cognitive impairment in pre-clinical trial. SOBIN-AD also reduced Aβ… Read More

#News

Alzheimer's disease drug
#Alzheimer's #Clinical trial #Neurodegenerative disorders

Novel therapeutic could treat neurodegenerative diseases 

A novel therapeutic could improve memory, cognitive function and neuroinflammation in neurodegenerative diseases.  VNA-318, developed by biotechnology company Vandria, was tested in preclinical mouse models of neurodegeneration and cognitive impairment. Data shows the candidate created an immediate improvement in memory, learning and cognitive function, as well… Read More

#News

#Alzheimer's #GLP-1 #Neurodegenerative disorders #Novo Nordisk #Obesity

Semaglutide shows no benefit in Alzheimer’s disease

Novo Nordisk has revealed that its Phase III trials of semaglutide (the active ingredient in Ozempic and Wegovy) did not demonstrate a statistically significant reduction in Alzheimer’s disease progression.  The top-line results from the two-year primary analysis of evoke and evoke+ Phase III trials in early-stage symptomatic… Read More

#Business & Investment #News #Trending News

Brain physiology
#Alzheimer's #Investment #Neurodegenerative disorders

Scripta raises $12 million to find disease-modifying drugs 

UK techbio company Scripta Therapeutics has announced it has raised $12 million to find disease-modifying drugs altering transcription factor activity.  The financing round was led by by Oxford Science Enterprises and Apollo Health Ventures, with AlbionVC, YZR Capital, and Parkwalk Advisors, with support from Oxford University Innovation. Read More

#Business & Investment #News

Drugs targeting amyloid Plaque
#Alzheimer's #Eli Lilly #European Commission #Neurodegenerative disorders #Neuroscience

European Commission extends EU use of Lilly’s donanemab

The European Commission (EC) has granted marketing authorisation for Lilly’s Kisunla (donanemab) in early symptomatic Alzheimer’s disease (AD).  It is approved in adults with mild cognitive impairment as well as those with mild dementia stages of AD with confirmed amyloid pathology who are apolipoprotein E (ApoE4) heterozygotes… Read More

#News #Regulatory

#Alzheimer's #Dementia #Neurodegenerative disorders #Neuroscience

What’s next for dementia drug research and development? 

To mark World Alzheimer’s Day on 21 September, Drug Discovery World speaks to biotech companies and investors at the forefront of next-generation dementia drugs.  After years of trudging through something akin to a Slough of Despond, dementia researchers, clinicians and patients have finally been given something to… Read More

#Exclusive Content

Neurons
#Alzheimer's #Neurodegenerative disorders #Neuroscience #Porosome Therapeutics

New Alzheimer’s therapy restores neurotransmission

Porosome Therapeutics has shared key advancements in its disease-modifying neurological platform, which it claims will transform Alzheimer’s Disease (AD) research and treatment by offering a new approach that goes beyond symptom management.   The company has demonstrated a relatively rapid reduction of the Alzheimer’s pathology in AD human… Read More

#News

Proteomics
#Alzheimer's #Collaboration #Nautilus Biotechnology #Neuroscience #Partnership #Proteomics

Nautilus forms partnership to better understand Alzheimer’s

Proteome analysis company Nautilus Biotechnology has announced a partnership with the Allen Institute focused on improving our understanding of neurodegenerative conditions.  The organisations will investigate the connection between the tau protein and its occurrence in neurodegenerative conditions such as Alzheimer’s disease.  Recent studies suggested that… Read More

#Business & Investment #News

#Alzheimer's #Drug discovery #Neurodegenerative disorders #Neuroscience

New DDW Highlights podcast: 4 August 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With the Alzheimer’s Association International Conference (AAIC) taking place this week in Toronto, Canada, there… Read More

#News

#Alzheimer's #Drug discovery #Neurodegenerative disorders #Neuroscience

This week in drug discovery (28 July – 1 August) 

News round-up for 28 July – 1 August by DDW Senior Digital Content Editor Diana Turner. With the Alzheimer’s Association International Conference (AAIC) taking place this week in Toronto, Canada, there have been a number of updates in the neuroscience drug discovery field. The top stories:… Read More

#News

#AltPep Corporation #Alzheimer's #Neuroscience #Peptides

Peptide for Alzheimer’s increases clearance of amyloid plaques

AltPep Corporation has presented new preclinical data on its lead compound, Soluble Oligomer Binding Inhibitor (SOBIN-AD), as a treatment for early Alzheimer’s disease (AD) at the Alzheimer’s Association International Conference (AAIC).   The preclinical data show SOBIN-AD:  Binds amyloid beta (Aβ) oligomers 27,000-fold stronger than… Read More

#News

Drugs targeting amyloid Plaque
#Alzheimer's #Neuroscience #Phase III trial #Roche

Roche’s AD study shows rapid clearance of amyloid plaques

Roche has shared new data from its Alzheimer’s development portfolio at the Alzheimer’s Association International Conference (AAIC) in Toronto, Canada.  Featured oral presentations include the latest results from the ongoing Phase Ib/IIa Brainshuttle Alzheimer’s disease (AD) study and design of the Phase III TRONTIER 1 and 2… Read More

#Editor's Choice #News